schliessen

Filtern

 

Bibliotheken

Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system.(Research Article)

Doxorubicin (DOX) is an anthracycline widely used for the treatment of solid and hematological tumors. The aim of this study was to assess the adverse event profiles of conventional DOX and liposomal DOX. This is the first study to evaluate the effect of a liposomal formulation of DOX using spontane... Full description

Journal Title: PLoS ONE Sept 27, 2017, Vol.12(9), p.e0185654
Main Author: Fukuda, Akiho
Other Authors: Tahara, Kohei , Hane, Yuuki , Matsui, Toshinobu , Sasaoka, Sayaka , Hatahira, Haruna , Motooka, Yumi , Hasegawa, Shiori , Naganuma, Misa , Abe, Junko , Nakao, Satoshi , Takeuchi, Hirofumi , Nakamura, Mitsuhiro
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0185654
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: gale_ofa506877605
title: Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system.(Research Article)
format: Article
creator:
  • Fukuda, Akiho
  • Tahara, Kohei
  • Hane, Yuuki
  • Matsui, Toshinobu
  • Sasaoka, Sayaka
  • Hatahira, Haruna
  • Motooka, Yumi
  • Hasegawa, Shiori
  • Naganuma, Misa
  • Abe, Junko
  • Nakao, Satoshi
  • Takeuchi, Hirofumi
  • Nakamura, Mitsuhiro
subjects:
  • Anthracyclines – Usage
ispartof: PLoS ONE, Sept 27, 2017, Vol.12(9), p.e0185654
description: Doxorubicin (DOX) is an anthracycline widely used for the treatment of solid and hematological tumors. The aim of this study was to assess the adverse event profiles of conventional DOX and liposomal DOX. This is the first study to evaluate the effect of a liposomal formulation of DOX using spontaneous reporting system (SRS) databases. The SRS used was the US Food and Drug Administration Adverse Event Reporting System (FAERS). This study relied on definitions of preferred terms provided by the Medical Dictionary for Regulatory Activities (MedDRA) and the standardized MedDRA Queries (SMQ) database. We also calculated the reporting odds ratios (RORs) of suspected drugs (conventional DOX; PEGylated-liposome DOX; non-PEGylated-liposome DOX). The FAERS database contained 7,561,254 reports from January 2004 to December 2015. The number of reported AE cases for conventional DOX, PEGylated-liposome DOX, and non-PEGylated-liposome DOX was 5039, 3780, and 349, respectively. Conventional DOX and liposomal DOX have potential risks of causing myelosuppression, cardiotoxicity, alopecia, nausea, and vomiting, among other effects. The RORs (95% CI) from SMQ for haematopoietic leucopenia associated with conventional DOX, PEGylated-liposome DOX, and non-PEGylated-liposome DOX were 12.75 (11.89-13.68), 6.43 (5.81-7.13), and 14.73 (11.42-18.99), respectively. Liposomal DOX formulations were associated with lower RORs with regard to myelosuppression, cardiotoxicity, and alopecia than the conventional DOX was. The RORs (95% CI) for palmar-plantar erythrodysesthesia (PPE) associated with conventional DOX, PEGylated-liposome DOX, and non-PEGylated-liposome DOX were 6.56 (4.74-9.07), 64.77 (56.84-73.80), and 28.76 (15.77-52.45), respectively. This study is the first to evaluate the relationship between DOX liposomal formulations and their adverse event profiles. The results indicate that careful observation for PPE is recommended with the use of liposomal DOX, especially PEGylated-liposome DOX formulations.
language: eng
source:
identifier: ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0185654
fulltext: fulltext
issn:
  • 1932-6203
  • 19326203
url: Link


@attributes
ID1058335738
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid506877605
sourceidgale_ofa
recordidTN_gale_ofa506877605
sourceformatXML
sourcesystemOther
pqid1944439325
galeid506877605
display
typearticle
titleComparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system.(Research Article)
creatorFukuda, Akiho ; Tahara, Kohei ; Hane, Yuuki ; Matsui, Toshinobu ; Sasaoka, Sayaka ; Hatahira, Haruna ; Motooka, Yumi ; Hasegawa, Shiori ; Naganuma, Misa ; Abe, Junko ; Nakao, Satoshi ; Takeuchi, Hirofumi ; Nakamura, Mitsuhiro
ispartofPLoS ONE, Sept 27, 2017, Vol.12(9), p.e0185654
identifierISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0185654
subjectAnthracyclines – Usage
descriptionDoxorubicin (DOX) is an anthracycline widely used for the treatment of solid and hematological tumors. The aim of this study was to assess the adverse event profiles of conventional DOX and liposomal DOX. This is the first study to evaluate the effect of a liposomal formulation of DOX using spontaneous reporting system (SRS) databases. The SRS used was the US Food and Drug Administration Adverse Event Reporting System (FAERS). This study relied on definitions of preferred terms provided by the Medical Dictionary for Regulatory Activities (MedDRA) and the standardized MedDRA Queries (SMQ) database. We also calculated the reporting odds ratios (RORs) of suspected drugs (conventional DOX; PEGylated-liposome DOX; non-PEGylated-liposome DOX). The FAERS database contained 7,561,254 reports from January 2004 to December 2015. The number of reported AE cases for conventional DOX, PEGylated-liposome DOX, and non-PEGylated-liposome DOX was 5039, 3780, and 349, respectively. Conventional DOX and liposomal DOX have potential risks of causing myelosuppression, cardiotoxicity, alopecia, nausea, and vomiting, among other effects. The RORs (95% CI) from SMQ for haematopoietic leucopenia associated with conventional DOX, PEGylated-liposome DOX, and non-PEGylated-liposome DOX were 12.75 (11.89-13.68), 6.43 (5.81-7.13), and 14.73 (11.42-18.99), respectively. Liposomal DOX formulations were associated with lower RORs with regard to myelosuppression, cardiotoxicity, and alopecia than the conventional DOX was. The RORs (95% CI) for palmar-plantar erythrodysesthesia (PPE) associated with conventional DOX, PEGylated-liposome DOX, and non-PEGylated-liposome DOX were 6.56 (4.74-9.07), 64.77 (56.84-73.80), and 28.76 (15.77-52.45), respectively. This study is the first to evaluate the relationship between DOX liposomal formulations and their adverse event profiles. The results indicate that careful observation for PPE is recommended with the use of liposomal DOX, especially PEGylated-liposome DOX formulations.
languageeng
source
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
scope
0gale_onefilea
1OneFile
creatorcontrib
0Fukuda, Akiho
1Akiho Fukuda; Kohei Tahara; Yuuki Hane; Toshinobu Matsui; Sayaka Sasaoka; Haruna Hatahira; Yumi Motooka; Shiori Hasegawa; Misa Naganuma; Junko Abe; Satoshi Nakao; Hirofumi Takeuchi; Mitsuhiro Nakamura
2Tahara, Kohei
3Hane, Yuuki
4Matsui, Toshinobu
5Sasaoka, Sayaka
6Hatahira, Haruna
7Motooka, Yumi
8Hasegawa, Shiori
9Naganuma, Misa
10Abe, Junko
11Nakao, Satoshi
12Takeuchi, Hirofumi
13Nakamura, Mitsuhiro
titleComparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system.(Research Article)
descriptionDoxorubicin (DOX) is an anthracycline widely used for the treatment of solid and hematological tumors. The aim of this study was to assess the adverse event profiles of conventional DOX and liposomal DOX. This is the first study to evaluate the effect of a liposomal formulation of DOX using spontaneous reporting system (SRS) databases. The SRS used was the US Food and Drug Administration Adverse Event Reporting System (FAERS). This study relied on definitions of preferred terms provided by the Medical Dictionary for Regulatory Activities (MedDRA) and the standardized MedDRA Queries (SMQ) database. We also calculated the reporting odds ratios (RORs) of suspected drugs (conventional DOX; PEGylated-liposome DOX; non-PEGylated-liposome DOX). The FAERS database contained 7,561,254 reports from January 2004 to December 2015. The number of reported AE cases for conventional DOX, PEGylated-liposome DOX, and non-PEGylated-liposome DOX was 5039, 3780, and 349, respectively. Conventional DOX and liposomal DOX have potential risks of causing myelosuppression, cardiotoxicity, alopecia, nausea, and vomiting, among other effects. The RORs (95% CI) from SMQ for haematopoietic leucopenia associated with conventional DOX, PEGylated-liposome DOX, and non-PEGylated-liposome DOX were 12.75 (11.89-13.68), 6.43 (5.81-7.13), and 14.73 (11.42-18.99), respectively. Liposomal DOX formulations were associated with lower RORs with regard to myelosuppression, cardiotoxicity, and alopecia than the conventional DOX was. The RORs (95% CI) for palmar-plantar erythrodysesthesia (PPE) associated with conventional DOX, PEGylated-liposome DOX, and non-PEGylated-liposome DOX were 6.56 (4.74-9.07), 64.77 (56.84-73.80), and 28.76 (15.77-52.45), respectively. This study is the first to evaluate the relationship between DOX liposomal formulations and their adverse event profiles. The results indicate that careful observation for PPE is recommended with the use of liposomal DOX, especially PEGylated-liposome DOX formulations.
subjectAnthracyclines–Usage
general
010.1371/journal.pone.0185654
1English
2Public Library of Science
3Cengage Learning, Inc.
sourceidgale_ofa
recordidgale_ofa506877605
issn
01932-6203
119326203
rsrctypearticle
creationdate2017
startdate20170927
enddate20170927
recordtypearticle
addtitlePLoS ONE
searchscopeOneFile
citationpf e0185654 vol 12 issue 9
lsr30VSR-Enriched:[pqid, pages, galeid]
sort
titleComparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system.(Research Article)
authorFukuda, Akiho ; Tahara, Kohei ; Hane, Yuuki ; Matsui, Toshinobu ; Sasaoka, Sayaka ; Hatahira, Haruna ; Motooka, Yumi ; Hasegawa, Shiori ; Naganuma, Misa ; Abe, Junko ; Nakao, Satoshi ; Takeuchi, Hirofumi ; Nakamura, Mitsuhiro
creationdate20170927
lso0120170927
facets
frbrgroupid8373955114001895967
frbrtype5
newrecords20171004
languageeng
creationdate2017
topicAnthracyclines–Usage
collectionOneFile (GALE)
prefilterarticles
rsrctypearticles
creatorcontrib
0Fukuda, Akiho
1Tahara, Kohei
2Hane, Yuuki
3Matsui, Toshinobu
4Sasaoka, Sayaka
5Hatahira, Haruna
6Motooka, Yumi
7Hasegawa, Shiori
8Naganuma, Misa
9Abe, Junko
10Nakao, Satoshi
11Takeuchi, Hirofumi
12Nakamura, Mitsuhiro
jtitlePLoS ONE
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Fukuda
1Tahara
2Hane
3Matsui
4Sasaoka
5Hatahira
6Motooka
7Hasegawa
8Naganuma
9Abe
10Nakao
11Takeuchi
12Nakamura
aufirst
0Akiho
1Kohei
2Yuuki
3Toshinobu
4Sayaka
5Haruna
6Yumi
7Shiori
8Misa
9Junko
10Satoshi
11Hirofumi
12Mitsuhiro
au
0Fukuda, Akiho
1Tahara, Kohei
2Hane, Yuuki
3Matsui, Toshinobu
4Sasaoka, Sayaka
5Hatahira, Haruna
6Motooka, Yumi
7Hasegawa, Shiori
8Naganuma, Misa
9Abe, Junko
10Nakao, Satoshi
11Takeuchi, Hirofumi
12Nakamura, Mitsuhiro
atitleComparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system.
jtitlePLoS ONE
risdate20170927
volume12
issue9
spagee0185654
issn1932-6203
formatjournal
genrearticle
ristypeJOUR
abstractDoxorubicin (DOX) is an anthracycline widely used for the treatment of solid and hematological tumors. The aim of this study was to assess the adverse event profiles of conventional DOX and liposomal DOX. This is the first study to evaluate the effect of a liposomal formulation of DOX using spontaneous reporting system (SRS) databases. The SRS used was the US Food and Drug Administration Adverse Event Reporting System (FAERS). This study relied on definitions of preferred terms provided by the Medical Dictionary for Regulatory Activities (MedDRA) and the standardized MedDRA Queries (SMQ) database. We also calculated the reporting odds ratios (RORs) of suspected drugs (conventional DOX; PEGylated-liposome DOX; non-PEGylated-liposome DOX). The FAERS database contained 7,561,254 reports from January 2004 to December 2015. The number of reported AE cases for conventional DOX, PEGylated-liposome DOX, and non-PEGylated-liposome DOX was 5039, 3780, and 349, respectively. Conventional DOX and liposomal DOX have potential risks of causing myelosuppression, cardiotoxicity, alopecia, nausea, and vomiting, among other effects. The RORs (95% CI) from SMQ for haematopoietic leucopenia associated with conventional DOX, PEGylated-liposome DOX, and non-PEGylated-liposome DOX were 12.75 (11.89-13.68), 6.43 (5.81-7.13), and 14.73 (11.42-18.99), respectively. Liposomal DOX formulations were associated with lower RORs with regard to myelosuppression, cardiotoxicity, and alopecia than the conventional DOX was. The RORs (95% CI) for palmar-plantar erythrodysesthesia (PPE) associated with conventional DOX, PEGylated-liposome DOX, and non-PEGylated-liposome DOX were 6.56 (4.74-9.07), 64.77 (56.84-73.80), and 28.76 (15.77-52.45), respectively. This study is the first to evaluate the relationship between DOX liposomal formulations and their adverse event profiles. The results indicate that careful observation for PPE is recommended with the use of liposomal DOX, especially PEGylated-liposome DOX formulations.
pubPublic Library of Science
doi10.1371/journal.pone.0185654
lad01gale_ofa
pagese0185654
date2017-09-27